earnings
confidence high
sentiment positive
materiality 0.85
GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M
GeneDx Holdings Corp.
2025-Q2 EPS reported
$0.14
revenue$189,807,000
- Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).
- Adjusted net income $15.0M vs. loss of $2.0M a year ago; GAAP net income $10.8M.
- Adjusted gross margin expanded to 71% from 62% in Q2 2024.
- Acquired Fabric Genomics for $33.2M in cash, net of cash acquired.
- AAP now recommends exome/genome as first-line test for children with global developmental delay.
item 2.02item 9.01